Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Monograph series

Melanocortin receptor agonists

Cyclic melanocortin analogues acting on pigmentation, appetite and sexual function.

All seriesIncretin receptor agonistsAmylin analoguesCombinations and unimolecular co-agonistsGrowth-hormone axisRepair and regenerationNeuroactive peptidesImmune modulatorsMitochondrial and metabolic cofactorsMelanocortin receptor agonistsReproductive-axis peptides

Monographs in this series

2 documents
  • Melanotan-II
    CEI-MN-049Melanocortin receptor agonistsUnapproved, research supply2 assessed outcomesversion 3.3

    Melanotan-II is a potent non-selective melanocortin receptor agonist. MC1R agonism stimulates eumelanin synthesis in melanocytes, producing pigmentation without ultraviolet exposure. MC4R agonism concurrently suppresses appetite…

    Very low02 Dec 2024
  • PT-141 (bremelanotide)
    CEI-MN-048Melanocortin receptor agonistsApproved1 assessed outcomeversion 4.1

    Bremelanotide activates central melanocortin-4 receptors, acting on hypothalamic and limbic circuits regulating sexual desire. Unlike phosphodiesterase-5 inhibitors it does not act on the peripheral vasculature. Its…

    Moderate15 Aug 2024
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.